Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Evolus stock | $8.15

Learn how to easily invest in Evolus stock.

Evolus Inc is a drug manufacturers-specialty & generic business based in the US. Evolus shares (EOLS) are listed on the NASDAQ and all prices are listed in US Dollars. Evolus employs 130 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Evolus

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EOLS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Evolus stock price (NASDAQ: EOLS)

Use our graph to track the performance of EOLS stocks over time.

Evolus shares at a glance

Information last updated 2021-10-18.
Latest market close$8.15
52-week range$2.85 - $17.38
50-day moving average $8.20
200-day moving average $10.41
Wall St. target price$17.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.37

Buy Evolus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Evolus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Evolus price performance over time

Historical closes compared with the close of $8.15 from 2021-10-22

1 week (2021-10-15) 6.26%
1 month (2021-09-24) 3.56%
3 months (2021-07-23) -25.23%
6 months (2021-04-23) -11.12%
1 year (2020-10-23) 132.19%
2 years (2019-10-24) -50.96%
3 years (2018-10-24) 13.3
5 years (2016-10-20) N/A

Evolus financials

Revenue TTM $76.6 million
Gross profit TTM $38.2 million
Return on assets TTM -16.71%
Return on equity TTM -175.44%
Profit margin -171.53%
Book value $1.95
Market capitalisation $418.6 million

TTM: trailing 12 months

Shorting Evolus shares

There are currently 2.4 million Evolus shares held short by investors – that's known as Evolus's "short interest". This figure is 1.1% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Evolus shares can be evaluated.

Evolus's "short interest ratio" (SIR)

Evolus's "short interest ratio" (SIR) is the quantity of Evolus shares currently shorted divided by the average quantity of Evolus shares traded daily (recently around 590225.43209877). Evolus's SIR currently stands at 4.05. In other words for every 100,000 Evolus shares traded daily on the market, roughly 4050 shares are currently held short.

However Evolus's short interest can also be evaluated against the total number of Evolus shares, or, against the total number of tradable Evolus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evolus's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Evolus shares in existence, roughly 40 shares are currently held short) or 0.0674% of the tradable shares (for every 100,000 tradable Evolus shares, roughly 67 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Evolus.

Find out more about how you can short Evolus stock.

Evolus share dividends

We're not expecting Evolus to pay a dividend over the next 12 months.

Evolus share price volatility

Over the last 12 months, Evolus's shares have ranged in value from as little as $2.85 up to $17.38. A popular way to gauge a stock's volatility is its "beta".

EOLS.US volatility(beta: 2.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evolus's is 2.3997. This would suggest that Evolus's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Evolus overview

Evolus, Inc. , a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. .

Frequently asked questions

What percentage of Evolus is owned by insiders or institutions?
Currently 34.072% of Evolus shares are held by insiders and 32.112% by institutions.
How many people work for Evolus?
Latest data suggests 130 work at Evolus.
When does the fiscal year end for Evolus?
Evolus's fiscal year ends in December.
Where is Evolus based?
Evolus's address is: 520 Newport Center Drive, Newport Beach, CA, United States, 92660
What is Evolus's ISIN number?
Evolus's international securities identification number is: US30052C1071
What is Evolus's CUSIP number?
Evolus's Committee on Uniform Securities Identification Procedures number is: 30052C107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site